These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 28596381)

  • 1. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
    Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
    J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile Acid G Protein-Coupled Membrane Receptor TGR5 Modulates Aquaporin 2-Mediated Water Homeostasis.
    Li S; Qiu M; Kong Y; Zhao X; Choi HJ; Reich M; Bunkelman BH; Liu Q; Hu S; Han M; Xie H; Rosenberg AZ; Keitel V; Kwon TH; Levi M; Li C; Wang W
    J Am Soc Nephrol; 2018 Nov; 29(11):2658-2670. PubMed ID: 30305310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice.
    Li Z; Huang J; Wang F; Li W; Wu X; Zhao C; Zhao J; Wei H; Wu Z; Qian M; Sun P; He L; Jin Y; Tang J; Qiu W; Siwko S; Liu M; Luo J; Xiao J
    J Bone Miner Res; 2019 Apr; 34(4):765-776. PubMed ID: 30536462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.
    Miyazaki-Anzai S; Masuda M; Levi M; Keenan AL; Miyazaki M
    PLoS One; 2014; 9(9):e108270. PubMed ID: 25237811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.
    Miyazaki-Anzai S; Masuda M; Kohno S; Levi M; Shiozaki Y; Keenan AL; Miyazaki M
    J Lipid Res; 2018 Sep; 59(9):1709-1713. PubMed ID: 29976576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
    Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
    J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.
    Baghdasaryan A; Claudel T; Gumhold J; Silbert D; Adorini L; Roda A; Vecchiotti S; Gonzalez FJ; Schoonjans K; Strazzabosco M; Fickert P; Trauner M
    Hepatology; 2011 Oct; 54(4):1303-12. PubMed ID: 22006858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes.
    Wang XX; Edelstein MH; Gafter U; Qiu L; Luo Y; Dobrinskikh E; Lucia S; Adorini L; D'Agati VD; Levi J; Rosenberg A; Kopp JB; Gius DR; Saleem MA; Levi M
    J Am Soc Nephrol; 2016 May; 27(5):1362-78. PubMed ID: 26424786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
    Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
    Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.
    Comeglio P; Cellai I; Mello T; Filippi S; Maneschi E; Corcetto F; Corno C; Sarchielli E; Morelli A; Rapizzi E; Bani D; Guasti D; Vannelli GB; Galli A; Adorini L; Maggi M; Vignozzi L
    J Endocrinol; 2018 Aug; 238(2):107-127. PubMed ID: 29945982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
    Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acid treatment and FXR agonism lower postprandial lipemia in mice.
    Farr S; Stankovic B; Hoffman S; Masoudpoor H; Baker C; Taher J; Dean AE; Anakk S; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G682-G693. PubMed ID: 32003602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acid receptors and the kidney.
    Herman-Edelstein M; Weinstein T; Levi M
    Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
    Brønden A; Knop FK
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.